Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.


Technoparkstrasse 1, 8005 Zürich, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business